BeyondSpring (NASDAQ:BYSI) Shares Up 2.4% – Here’s Why

BeyondSpring Inc. (NASDAQ:BYSI) shares rose 2.4% during mid-day trading on Tuesday . The stock traded as high as $1.3399 and last traded at $1.30. Approximately 13,361 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 26,595 shares. The stock had previously closed at $1.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

BeyondSpring Stock Performance

The firm has a 50-day moving average of $1.68 and a 200-day moving average of $1.82. The firm has a market capitalization of $52.43 million, a P/E ratio of -8.67 and a beta of 0.54.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC raised its position in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 256,212 shares of the company’s stock after buying an additional 231,844 shares during the period. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 at the end of the most recent reporting period. Institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.